2022. Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s46. DOI:https://doi.org/10.25251/skin.6.supp.46.